Literature DB >> 18983627

Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis.

Jannette M Parr1, David J Kavanagh, Lareina Cahill, Geoffrey Mitchell, Ross McD Young.   

Abstract

AIMS: To assess the effectiveness of current treatment approaches to assist benzodiazepine discontinuation.
METHODS: A systematic review of approaches to benzodiazepine discontinuation in general practice and out-patient settings was undertaken. Routine care was compared with three treatment approaches: brief interventions, gradual dose reduction (GDR) and psychological interventions. GDR was compared with GDR plus psychological interventions or substitutive pharmacotherapies.
RESULTS: Inclusion criteria were met by 24 studies, and a further eight were identified by future search. GDR [odds ratio (OR) = 5.96, confidence interval (CI) = 2.08-17.11] and brief interventions (OR = 4.37, CI = 2.28-8.40) provided superior cessation rates at post-treatment to routine care. Psychological treatment plus GDR were superior to both routine care (OR = 3.38, CI = 1.86-6.12) and GDR alone (OR = 1.82, CI = 1.25-2.67). However, substitutive pharmacotherapies did not add to the impact of GDR (OR = 1.30, CI = 0.97-1.73), and abrupt substitution of benzodiazepines by other pharmacotherapy was less effective than GDR alone (OR = 0.30, CI = 0.14-0.64). Few studies on any technique had significantly greater benzodiazepine discontinuation than controls at follow-up.
CONCLUSIONS: Providing an intervention is more effective than routine care. Psychological interventions may improve discontinuation above GDR alone. While some substitutive pharmacotherapies may have promise, current evidence is insufficient to support their use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983627     DOI: 10.1111/j.1360-0443.2008.02364.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  45 in total

1.  Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: family physicians' attitudes toward benzodiazepine prescribing.

Authors:  Sibyl Anthierens; Inge Pasteels; Hilde Habraken; Pascale Steinberg; Tom Declercq; Thierry Christiaens
Journal:  Can Fam Physician       Date:  2010-11       Impact factor: 3.275

Review 2.  Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Authors:  Brendan J Ng; David G Le Couteur; Sarah N Hilmer
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

3. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

4.  Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Authors:  Ritva Lähteenmäki; Juha Puustinen; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

5.  Potentially inappropriate prescribing in an Irish elderly population in primary care.

Authors:  Cristín Ryan; Denis O'Mahony; Julia Kennedy; Peter Weedle; Stephen Byrne
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

6.  A prevalence study of potentially inappropriate prescribing in Irish long-term care residents.

Authors:  David P O'Sullivan; Denis O'Mahony; Carole Parsons; Carmel Hughes; Kevin Murphy; Susan Patterson; Stephen Byrne
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

7.  Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study.

Authors:  Jolyce Bourgeois; Monique M Elseviers; Luc Van Bortel; Mirko Petrovic; Robert H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2014-08-08       Impact factor: 2.953

Review 8.  Benzodiazepine harm: how can it be reduced?

Authors:  Malcolm Lader
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 9.  Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Authors:  Malcolm Lader; Andri Kyriacou
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

10.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.